Intermittent treatment of BRAFV600E melanoma cells delays resistance by adaptive resensitization to drug rechallenge
Journal Article
Overview
publication date
- March 22, 2022
has subject area
- Biochemical Phenomena - MAP Kinase Signaling System
- Cell Line - Cell Line, Tumor
- Cell Physiological Phenomena - MAP Kinase Signaling System
- Drug Resistance, Neoplasm
- Humans
- Metabolic Networks and Pathways - MAP Kinase Signaling System
- Mutation
- Neoplasms, Germ Cell and Embryonal - Melanoma
- Neoplasms, Nerve Tissue - Melanoma
- Nevi and Melanomas - Melanoma
- Peptides - Mitogen-Activated Protein Kinases
- Peptides - Proto-Oncogene Proteins B-raf
- Protein Kinase Inhibitors
- Protein-Serine-Threonine Kinases - Mitogen-Activated Protein Kinases
- Protein-Serine-Threonine Kinases - Proto-Oncogene Proteins B-raf
- Proteins - Mitogen-Activated Protein Kinases
- Proteins - Proto-Oncogene Proteins B-raf
- Proto-Oncogene Proteins - Proto-Oncogene Proteins B-raf
- Tumor Cells, Cultured - Cell Line, Tumor
has restriction
- hybrid
Date in CU Experts
- February 23, 2022 4:32 AM
Full Author List
- Kavran AJ; Stuart SA; Hayashi KR; Basken JM; Brandhuber BJ; Ahn NG
author count
- 6
citation count
- 14
published in
Other Profiles
International Standard Serial Number (ISSN)
- 0027-8424
Electronic International Standard Serial Number (EISSN)
- 1091-6490
Digital Object Identifier (DOI)
Additional Document Info
volume
- 119
issue
- 12
number
- ARTN e2113535119